E.g., 06/24/2021
E.g., 06/24/2021

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch 

06 May, 2020

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

04 May, 2020

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

24 March, 2020

First of 3 diagnostic tests for  SARS-CoV-2 coronavirus available from bioMérieux

11 March, 2020

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

14 January, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.d about 9,800.

NEPHROCHECK® Biomarkers TIMP-2 and IGFBP7 Included in the ERAS “Guidelines for Perioperative Care in Cardiac Surgery”

15 May, 2019

“Global-PPS”, a survey of antibiotic use and bacterial resistance in hospitals worldwide, tops the 200,000 patients

15 April, 2019

Baxter and bioMérieux announce collaboration to improve identification and treatment of acute kidney injury

19 March, 2019

bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking

13 November, 2018

bioMérieux acquires a majority stake in Hybiome and strengthens its presence both in China and in the immunoassay market

09 November, 2018

Pioneering diagnostics